Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs GeneDx Holdings Corp (WGS) Price & Performance

iShares Russell 2000 ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs GeneDx Holdings Corp — how do they compare? iShares Russell 2000 ETF trades at $296.11, while GeneDx Holdings Corp trades at $60.56 (market cap $1.80B). The key difference: iShares Russell 2000 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

IWMWGS
52-Week High
$300.45$167.51
52-Week Low
$214.95$34.51
Market Cap
$1.80B
Sector
Technology
Enterprise Value
$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM, the iShares Russell 2000 ETF, trades at $292.34, down 0.6% on the day. Technical indicators are mixed with a neutral overall signal, while moving averages show a bullish bias. The ETF has seen strong institutional inflows, with firms like AIA Group and Allspring Global Investments increasing their holdings significantly in Q1 2026 (SEC 13F filings, July 2026). Small-cap stocks have outperformed large-caps year-to-date, with the Russell 2000 up approximately 20% in 2026 (24/7 Wall Street, July 17, 2026).

The outlook for IWM hinges on continued small-cap strength, which is sensitive to interest rates and economic growth. While recent performance is robust, risks include higher volatility versus large-caps and potential Fed policy shifts. Analyst sentiment is divided, with some highlighting valuation concerns versus broader market ETFs.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS